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Abstract
Treatment-resistant depression is a difficult problem in clinical practice. 
Evidence for the efficacy of newer antidepressants, such as duloxetine 
and bupropion, is not yet well established. We present a case of treatment-
resistant depression with full recovery where a combination of mirtazapine 
and bupropion was used after a failed response to combined mirtazapine 
and duloxetine treatment. [Tzu Chi Med J 2009;21(4):352–354]
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1. Introduction
Treatment-resistant depression (TRD) is a difficult prob-
lem for clinical psychiatrists. A definition used in the 
past is the absence of a clinical response to treat-
ment with a tricyclic antidepressant at a minimum 
dose of 150 mg/day of imipramine (or an equivalent 
drug) for 4–6 weeks [1]. However, there have been a 
number of different definitions of TRD used in various 
studies [2,3] and a consensus has yet to be reached. 
There is still a lack of adequate evidence to support 
any particular approach to TRD management in clini-
cal practice. According to previous studies, switching, 
augmentation, combination, and non-pharmacological, 
that is psychosocial intervention, strategies have all 
been suggested [4–6]. Numerous augmentation thera-
pies, such as the use of steroids, buspirone, pindolol 
and atypical antipsychotics, have been suggested, 
but there is a lack of adequate double-blinded clini-
cal trial evidence to support the use of any of these 
[7,8]. In addition, the presence of various side effects, 
such as metabolic syndrome and endocrine system 
disturbance, would seem to render these agents rel-
atively unsuitable. Lithium, even with the strongest 
evidence of efficacy as a first-line augmentation ther-
apy [9], has well-known side effects, which include 
dry mouth, nephrotoxicity and neurotoxicity. When 
examined from a patient-centered perspective, these 
agents are not first-line options due to their possible 
side effects, which might affect patient compliance 
with medication. Combined treatment using different 
antidepressants, such as a selective serotonin reuptake 
inhibitor (SSRI) combined with a serotonin norepi-
nephrine reuptake inhibitor (SNRI), norepinephrine 
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reuptake inhibitor and tricyclic antidepressant, have 
been published in a review of TRD therapeutic options 
[10]. Newer antidepressants, such as mirtazapine, du-
loxetine and bupropion, have, as yet, no clear roles 
in such treatment regimens. Here, we present a case 
of TRD in which combined therapy using these newer 
antidepressants was used.
2. Case report
A 54-year-old married man had his first episode of 
major depressive disorder about 5 years ago due to 
business-associated financial problems and the stress 
of working in the Republic of South Africa. He was 
treated with an SSRI initially, but then stopped treat-
ment within 4 weeks because of poor response. His 
psychiatrist switched the prescribed antidepressant 
to mirtazapine in anticipation of a better response. 
Nevertheless, after 2 weeks of treatment with a dose 
of 60 mg/day, he continued to feel depressed; fur-
thermore, he continued to harbor thoughts of suicide 
and suffered from generalized physical discomfort. 
At this point, he began to receive mirtazapine com-
bined with duloxetine at a dose of 60 mg/day and his 
mood condition improved after 4 weeks. Finally, his 
depression achieved full remission after 6 months of 
treatment with mirtazapine and duloxetine. Over the 
next few years, no further depressive episodes were 
observed.
He returned to Taiwan about 1 year ago on his fa-
ther’s death. He began to suffer from depressed 
mood and showed lack of interest, lack of energy, 
restlessness, nervousness, anxiety, thoughts of sui-
cide, and feelings of helplessness, hopelessness and 
worthlessness. There was also the presence of psy-
chomotor retardation and overall generalized physi-
cal discomfort, including palm sweatiness, chills and 
fatigue. These had occurred over a 2–3-month period 
since his arrival in Taiwan. No systemic disease, sub-
stance dependence or substance abuse were noted. 
The feelings of physical discomfort did not fulfill the 
Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition, Text Revision (DSM-IV-TR) 
panic attack diagnostic criteria. His Quick Inventory of 
Depressive Symptomatology–Self Report (QIDS-SR) 
score was 40 (out of a total of 48), and his Integral 
Inventory for Depression (IID) score was 47 (out of 
a total of 60). At that time, he was initially treated 
with mirtazapine 60 mg/day, but his depression 
symptoms and somatic complaints were not relieved. 
In addition, he was unable to carry out many of his 
daily life activities, such as cooking. Combined treat-
ment with duloxetine 60 mg/day was started due to 
the persistent depression. After another month of 
treatment, immobility for a large part of the day, de-
pressed mood, general physical discomfort, difficulty 
remaining in a chair when sitting, and strong thoughts 
of suicide continued to be experienced. His QIDS-SR 
and IID scores were 35 and 46, respectively, at this 
time. After discussion with the patient and his wife, 
it was decided that the duloxetine dose would not be 
titrated but replaced with bupropion 300 mg/day.
Over the next 2 weeks, his mood improved and 
the patient demonstrated more energy in his usual 
activities, a greater motivation to interact with his 
family members, less palm sweating, less forehead 
sweating, less irritability and fewer ideas of suicide. 
On assessment, his QIDS-SR and IID scores had im-
proved to 10 and 16, respectively, and no specific side 
effects were complained of. After 1 month of com-
bined treatment with mirtazapine and bupropion, his 
depression had achieved near full remission (QIDS-SR, 
3; IID, 5).
3. Discussion
The hypothetical biological pathogenesis model for 
major depressive disorder includes changes in three 
major neurotransmitters: serotonin, norepinephrine 
and dopamine [11]. All antidepressants currently in 
use are established on the basis of this “neurotrans-
mitter model”. In previously published articles, pre-
scription suggestions for the treatment of TRD can 
be divided into two major categories, combined 
treatment and augmentation therapy. For combined 
treatment with two antidepressants, reports have 
usually suggested that an SSRI with an SNRI or a 
norepinephrine reuptake inhibitor be the first choice. 
In addition, as dopamine’s role in depression has 
become more prominent over the last few years [12], 
a norepinephrine-dopamine reuptake inhibitor com-
bination seems to have become another new choice. 
In this patient, a new SNRI, duloxetine, was combined 
with mirtazapine in anticipation that a serotonin re-
ceptor 5-hydroxytryptamine 1A agonist effect from 
mirtazapine [13] might elicit a better response than 
the single serotonin and norepinephrine reuptake in-
hibition effect of duloxetine. Even after a previous 
successful response to combined treatment with 
mirtazapine and duloxetine, the patient failed to re-
spond to such a combination in the recent episode. 
The inadequate response might be related to one of 
the following: the absence of dopamine reuptake in-
hibition, a different episode with divergent symptoms, 
the dose level of duloxetine and/or the duration of 
therapy. In these circumstances, a different additional 
neurotransmitter strategy, targeting dopamine, might 
be considered an appropriate approach to this type 
of treatment-resistant condition.
The dopamine reuptake inhibition mechanism has 
been hypothesized as a new strategy for the treatment 
of major depression. A dopamine-deficiency animal 
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model has been reported to show symptoms similar 
to depression, including learned helplessness, im-
mobility, decreased appetite and fear [14]. Bupropion 
is a norepinephrine-dopamine reuptake inhibitor-type 
antidepressant, which has been reported to improve 
low energy symptoms in major depression [15]. Our 
clinical experience with this patient suggests that we 
should consider combining all three neurotransmitters 
into our treatment strategies when tackling TRD.
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